Mayank Chaturvedi
1, Manish Kumar
2*, Kamla Pathak
3, Shailendra Bhatt
2, Vipin Saini
21 Department of Pharmaceutics, Rajiv Academy for Pharmacy, Chattikkara, Mathura, India.
2 Department of Pharmaceutics, M M College of Pharmacy, Maharishi Markandeshwar University,Mullana, Ambala-133207, Haryana, India.
3 Department of Pharmaceutics, Pharmacy College Saifai, Uttar Pradesh University of Medical sciences, Saifai, Etawah , 206130, Uttar Pradesh, India.
Abstract
Purpose:
A comparative study was carried out between surface solid dispersion (SSD) and
solid dispersion (SD) of meloxicam (MLX) to assess the solubility and
dissolution enhancement approach and thereafter develop as patient friendly
orodispersible tablet.
Methods:
Crospovidone (CPV), a hydrophilic carrier was selected for SSD preparation on
the basis of 89% in- vitro MLX adsorption, 19% hydration capacity and high
swelling index. SD on the other hand was made with PEG4000. Both were prepared
by co-grinding and solvent evaporation method using drug: carrier ratios of
1:1, 1:4, and 1:8. Formulation SSDS3 (MLX: CPV in 1:8 ratio) made by solvent
evaporation method showed t50%
of 28 min and 80.9% DE50min which
was higher in comparison to the corresponding solid dispersion, SDS3 (t50%
of 35min and 76.4% DE50min).
Both SSDS3 and SDS3 were developed as orodispersible tablets and evaluated.
Results: Tablet formulation F3 made with SSD3 with a disintegration time of 11
secs, by wetting time= 6 sec, high water absorption of 78%by wt and cumulative
drug release of 97% proved to be superior than the tablet made with SD3.
Conclusion: Conclusively, the SSD of meloxicam has the potential to be developed as
fast acing formulation that can ensure almost complete release of drug.